Spontaneous Abortion

Slide 1 · Spontaneous Abortion

Etiologic mechanisms • Placental context • Clinicopathologic reasoning

Pathology lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

By the end of this lecture, you should be able to:

Define spontaneous abortion using the gestational boundary stated.

Interpret the reported frequencies without mixing different denominators.

Organize fetal and maternal etiologic contributors into mechanistic domains.

Relate pregnancy loss to the maternal–fetal interface and interpret uncertainty.

Slide 3 · Miscarriage: The textbook definition

Spontaneous abortion = miscarriage

Pregnancy loss before 20 weeks of gestation (the boundary used in this source).

The term describes the outcome, not a single etiologic disease.

The source identifies numerous fetal and maternal contributors.

Terminology

The gestational threshold is edition- and jurisdiction-dependent; This lecture uses the explicit Robbins definition.

Definition is an outcome category; Causation requires separate analysis.

Slide 4 · Gestational timing: The reported distribution

Time window adapted to the source statement; Not drawn to scale

Conception

Early pregnancy

Before 12 weeks

Most spontaneous abortions

12 to <20 weeks

Smaller share of spontaneous abortions

The source emphasizes concentration in the earliest part of pregnancy.

Slide 5 · Clinically recognized pregnancies

10–15%

Terminate in spontaneous abortion

The percentage refers to clinically recognized pregnancies.

Not all conceptions are clinically detected.

Interpret this frequency within its explicitly defined denominator.

Do not treat this estimate as a percentage of all conceptions.

Slide 6 · Additional early losses detected by sensitive assays

~20%

Additional early pregnancies terminate spontaneously

Sensitive chorionic gonadotropin assays detect losses not routinely recognized.

These in otherwise healthy females.

This is a distinct ascertainment context from clinically recognized pregnancy.

An additional early-loss estimate; Denominators are not interchangeable.

Slide 7 · Frequency statements have different denominators

Observation

Population / detection

What to infer

10–15%

Clinically recognized pregnancies

Frequency after clinical recognition

Additional ~20%

Early pregnancy recognized with sensitive hCG assays

Earlier losses can escape clinical recognition

Most before 12 wk

Spontaneous abortions

Early gestations dominate the timing distribution

Ascertainment method matters when interpreting pregnancy-loss epidemiology.

Slide 8 · Pregnancy loss is etiologically heterogeneous

One clinical outcome; Multiple potential biological routes

Fetal genetic abnormalities are prominent in early abortuses.

Maternal endocrine, structural, vascular, infectious and immune factors also appear.

These categories describe possible contributors, not mutually exclusive diagnoses.

Different pathways may converge on inability to maintain gestation.

Slide 9 · Six major etiologic domains in the source

Fetal genetics

Aneuploidy • polyploidy • translocations

Maternal endocrine

Luteal-phase defect • diabetes

Uterine anatomy

Leiomyoma • polyp • malformation

Maternal vasculature

APS • coagulopathy • hypertension

Infection

Protozoa • bacteria • viruses

Immune tolerance

Innate/adaptive balance • regulatory T cells

Slide 10 · An unknown mechanism is a valid outcome

Causal assignment has limitations

The mechanism of most individual early losses is unknown.

Identifying a potential contributor does not prove it caused one specific loss.

The lecture separates source-established categories from explanatory teaching schematics.

Inference discipline

Association, biologic plausibility and demonstrated individual causation are different evidentiary levels.

Do not transform a risk category into a case-specific diagnosis.

Slide 11 · Fetal and maternal domains: An organizing distinction

The clinical endpoint does not specify the compartment

Fetal: Chromosomal abnormalities and additional genetic defects.

Maternal: Endocrine environment, uterine anatomy, vascular status and infection.

Interface: Placentation and maternal tolerance of fetal trophoblast.

Why this matters

A category-specific problem can arise before, during, or after implantation.

Partition the potential mechanism before interpreting the clinical finding.

Slide 12 · Placental biology provides essential context

Maternal and fetal structures are functionally coupled

Chorionic villi form branching exchange structures.

Villous trophoblast mediates transport, hormonal secretion and barrier function.

Invasive extravillous trophoblast establishes maternal attachment and vascular remodeling.

Normal placental development depends on both fetal-derived tissue and maternal response.

Slide 13 · The trophoblast lineage has distinct functions

Cytotrophoblast

Villus-covering epithelial component

Forms a discrete layer in early villi

Syncytiotrophoblast

Villus-covering epithelial component

Exchange, hormone secretion, barrier

Extravillous trophoblast

Invasive placental cells

Anchors placenta and remodels vessels

Do not conflate the villous exchange surface with invasive extravillous cells.

Slide 14 · Normal early chorionic villus: Tissue architecture

Native schematic — not a histologic image

Central villous stroma

Syncytiotrophoblast

Outer epithelial layer

Cytotrophoblast

Inner epithelial layer

Early villi have two distinguishable trophoblast layers around central stroma.

Slide 15 · First-trimester villi have two epithelial layers

Description of the normal reference architecture

A delicate central stromal mesh occupies the villus core.

An inner layer of cytotrophoblast is readily identifiable.

An outer syncytiotrophoblast layer surrounds the cytotrophoblast.

The parent textbook figure depicts normal tissue—not a specific miscarriage lesion.

Slide 16 · The mature villus has a thinner exchange barrier

Gestational remodeling changes normal morphology

By the third trimester, villous capillaries form a dense, dilated network.

Syncytiotrophoblast becomes thin near fetal capillary endothelium.

The cytotrophoblast layer is substantially diminished.

Do not compare villi from different gestational ages as though they share identical baseline morphology.

Slide 17 · Maternal and fetal circulations remain distinct

Original conceptual diagram — no mixing under normal circumstances

MATERNAL CIRCULATION

FETAL CIRCULATION

Spiral arteries → intervillous blood

Umbilical arteries → villous capillaries

Exchange across trophoblast + capillary interface

Maternal blood occupies the intervillous space; Fetal blood remains within fetal vessels.

Slide 18 · Maternal perfusion reaches the intervillous space

Conceptual pathway (schematic)

Maternal spiral arteries

Enter placental bed

Intervillous space

Maternal blood surrounds villi

Villous interface

Fetal exchange across barrier

The parent chapter places the onset of maternal blood entry at approximately 10–12 weeks.

Maternal blood remains outside fetal vessels in a normal placenta.

Slide 19 · Fetal vessels follow a separate route

Conceptual pathway (schematic)

Two umbilical arteries

Carry fetal blood toward placenta

Villous capillaries

Exchange across placental barrier

Single umbilical vein

Returns oxygenated blood to fetus

Maternal and fetal circulations are juxtaposed for exchange but normally remain separate.

Slide 20 · Extravillous trophoblast and the uterine vessel

Conceptual pathway (schematic)

Extravillous trophoblast

Invasive fetal-derived cells

Maternal vessel remodeling

Spiral arteries transformed

Perfusion adaptation

Low-pressure, high-capacitance system

Successful placentation relies on carefully regulated invasion and maternal vascular adaptation.

This is normal physiology; It is not proof of a specific mechanism in a given miscarriage.

Slide 21 · What does this source establish about morphology?

Normal placental structure is described; Miscarriage morphology is not

The adjacent parent section describes normal villi and placental circulation.

The spontaneous-abortion section principally lists etiologic categories.

It does not provide a validated histologic pattern or diagnostic tissue criterion for each mechanism.

A diagnostic photomicrograph cannot be invented to fill a source gap.

Slide 22 · Fetal chromosomal abnormalities are prominent

Genomic defects form the largest quantified category in this excerpt

Aneuploidy, polyploidy and translocations.

These abnormalities are reported in approximately half of early abortuses.

Additional, subtler genetic defects may be missed by routine testing.

A chromosomal result is informative, but not every loss is chromosomally explained.

Slide 23 · Chromosomal findings in early abortuses

~50%

Have fetal chromosomal anomalies

The observation concerns examined early abortuses.

The named examples are aneuploidy, polyploidy and translocations.

It does not assert that 50% of all pregnancies have such anomalies.

The 50% figure is not a maternal risk estimate or a predicted individual recurrence rate.

Slide 24 · Aneuploidy: Abnormal chromosome number

A fetal genomic category explicitly named in the source

Aneuploidy refers to gain or loss of individual chromosomes.

It belongs to the group of chromosomal abnormalities reported in early abortuses.

The source does not specify the frequency of any individual trisomy or monosomy.

Interpretive point

A genetic category can explain a failed gestation without identifying a maternal disorder.

Avoid inventing chromosome-specific proportions.

Slide 25 · Polyploidy: Alteration of whole chromosome sets

Different from gain or loss of a single chromosome

Polyploidy denotes additional complete chromosome complements.

It is one of the three examples of chromosomal anomalies in early abortuses.

The Robbins excerpt does not assign a separate rate or a characteristic morphology.

Comparison

Aneuploidy alters individual chromosome number; Polyploidy alters complete chromosome sets.

Slide 26 · Translocations: Chromosomal rearrangements

Structural chromosome changes are a distinct category

Translocations rearrange chromosome segments between chromosomes.

They are included among abnormalities found in early abortuses.

The excerpt provides no subclassification, parental carrier rate or recurrence estimate.

The presence of a rearrangement category does not justify case-specific counseling numbers.

Slide 27 · Three chromosomal categories: Do not conflate

Category

Basic genetic change

Textbook claim

Aneuploidy

Abnormal individual chromosome number

Named in early abortuses

Polyploidy

Altered number of chromosome sets

Named in early abortuses

Translocation

Chromosome segment rearrangement

Named in early abortuses

These are classification examples; The excerpt does not rank them individually.

Slide 28 · More subtle fetal genetic defects may escape detection

A normal routine result does not establish genetic normality

An additional fraction of early loss from subtle genetic defects.

Routine genetic testing may not be available for these defects.

The source does not quantify that additional fraction.

Do not force every unexplained loss into the measured chromosomal category.

Slide 29 · Interpreting a genetic result requires restraint

Distinguish observation from an etiologic conclusion

A chromosomal abnormality in abortus tissue supplies mechanistic evidence.

A measured proportion in early abortuses does not determine the cause of every loss.

Test availability and resolution constrain the interpretation.

Reporting discipline

Describe what was demonstrated and what remains unresolved.

Source does not supply a universal testing algorithm.

Slide 30 · Maternal endocrine disorders are a separate domain

Gestation also requires a supportive maternal endocrine environment

Robbins explicitly lists luteal-phase defect.

Poorly controlled diabetes is also included.

Other endocrine disorders are acknowledged but not enumerated in this passage.

The excerpt identifies endocrine etiologies without defining laboratory cutoffs.

Slide 31 · Luteal-phase defect: The named endocrine contributor

Conceptual pathway (schematic)

Luteal-phase defect

Endocrine disturbance

Maternal environment

Support of early gestation may be inadequate

Pregnancy loss

Listed as a potential contributor

This is an explanatory teaching sequence. The defect but does not establish a test or individual causal pathway.

No biochemical diagnostic threshold is given in this source.

Slide 32 · Poorly controlled diabetes is a maternal factor

The qualifier “poorly controlled” matters

The named contributor is poorly controlled diabetes, not diabetes under all conditions.

It appears under maternal endocrine etiologies.

The excerpt does not provide glycemic thresholds, odds ratios, or management targets.

Do not imply a patient-specific risk estimate without additional evidence.

Slide 33 · Other endocrine disorders: A defined source limit

The textbook acknowledges a category without naming every member

The expression “other endocrine disorders” broadens the maternal endocrine domain.

This excerpt does not identify which disorders qualify or their relative contributions.

Avoid substituting a fabricated exhaustive endocrine checklist.

Instructional discipline

When teaching from a short excerpt, a stated information gap is preferable to an unsupported numerical or diagnostic claim.

Additional detail requires separately identified external evidence.

Slide 34 · Uterine anatomy can impair implantation

The mechanism named by Robbins is mechanical disruption

Submucosal leiomyomas and uterine polyps are examples.

Uterine malformations provide a third structural category.

Such lesions may prevent or disrupt implantation.

The key link is location/architecture → implantation disturbance.

Slide 35 · Submucosal leiomyoma: The proposed interface

Conceptual pathway (schematic)

Submucosal lesion

Local uterine architectural abnormality

Implantation region

May be affected by the lesion

Pregnancy maintenance

Implantation may fail or be disrupted

Source supports a possible implantation mechanism; It does not specify lesion-size thresholds.

A leiomyoma elsewhere in the uterus is not automatically the proven cause.

Slide 36 · Uterine polyps are another structural example

A focal intrauterine lesion can affect the implantation site

Polyps are explicitly listed in the physical-anomaly group.

Their relevance is conceptualized through interference with implantation.

The passage supplies no polyp size, location rule, or comparative risk estimate.

The source establishes a possible causal category, not a numerical severity scale.

Slide 37 · Uterine malformations alter the implantation setting

The relevant feature is the overall uterine configuration

Congenital or other malformations are listed as structural contributors.

They can be considered distinct from localized masses and polyps.

The passage does not provide malformation types or outcome frequencies.

Do not invent subtype-specific pregnancy-loss rates.

Slide 38 · Structural factors differ in the type of abnormality

Example

Anatomic characterization

Mechanism in source

Submucosal leiomyoma

Myometrial lesion near cavity

May prevent/disrupt implantation

Uterine polyp

Focal intrauterine growth

May prevent/disrupt implantation

Uterine malformation

Abnormal uterine configuration

May prevent/disrupt implantation

The shared mechanistic endpoint is implantation interference.

Slide 39 · Maternal vascular conditions form another domain

Abnormal systemic vascular status can affect gestation

Antiphospholipid antibody syndrome.

Coagulopathies are named as a broader category.

Hypertension is the third explicit example.

Vascular contributors differ from physical interruption of implantation.

Slide 40 · Antiphospholipid antibody syndrome is named

A systemic maternal disorder affecting vasculature

The condition appears among maternal vascular causes of miscarriage.

The excerpt does not set laboratory persistence criteria or obstetric diagnostic criteria.

Its recognition in a pathology framework does not replace a formal clinical diagnostic standard.

Avoid supplying unverified antibody cutoffs or treatment regimens.

Slide 41 · Coagulopathies: A broad vascular-risk category

Robbins does not name a single inherited or acquired subtype here

Coagulopathies are explicitly included under systemic disorders affecting vasculature.

The source does not equate all coagulation abnormalities with pregnancy loss.

Mechanism, causality and testing details require evidence beyond the excerpt.

Do not presume every thrombophilia is causally established.

Slide 42 · Hypertension: A maternal systemic contributor

The source links vascular maternal disease to pregnancy-loss etiologies

Hypertension is the named cardiovascular example.

The excerpt does not subdivide chronic versus pregnancy-specific hypertension.

It does not provide a pressure threshold or risk ratio for early miscarriage.

The cause category should not be converted into a diagnostic prediction.

Slide 43 · Structural and vascular contributors are different

Question

Uterine structural domain

Maternal vascular domain

Primary issue

Anatomy / implantation setting

Systemic vascular disorder

Examples

Fibroid, polyp, malformation

APS, coagulopathy, hypertension

Mechanistic emphasis

May prevent or disrupt implantation

Maternal vasculature affects gestation

The two domains may coexist, but should not be treated as synonyms.

Slide 44 · Infectious causes include multiple pathogen classes

Organisms without quantifying individual risks

Protozoal infection: Toxoplasma.

Bacterial examples: Mycoplasma and Listeria.

Certain viruses are also recognized, without naming specific viruses in this excerpt.

A named pathogen category is not equivalent to proof of infection in a case.

Slide 45 · Ascending infection: Route from lower genital tract

Conceptual pathway (schematic)

Cervicovaginal vault

Lower-tract infectious source

Ascending spread

Moves toward gestational tissues

Placenta / fetus

Potential infectious involvement

This route as particularly common in second-trimester pregnancy loss.

Route is specified; Diagnostic microbiology criteria are not.

Slide 46 · Hematogenous infection: A distinct route

Conceptual pathway (schematic)

Maternal circulation

Bloodborne infectious exposure

Placental arrival

Organisms may reach placenta

Fetal exposure

Potential spread to fetus

The source names hematogenous transmission as an alternative to ascending infection.

These pathways describe route of entry, not a uniform lesion pattern.

Slide 47 · Second-trimester loss: Infectious timing clue

Ascending lower-genital-tract infection is especially relevant

The source singles out ascending infection from the cervicovaginal vault.

It calls this route a particularly common cause of second-trimester losses.

This does not imply that every second-trimester loss is infectious.

Gestational timing provides context, not a definitive etiologic test.

Slide 48 · Pathogen classes and routes are distinct axes

Axis

Textbook examples

Interpretation

Pathogen class

Toxoplasma; Mycoplasma; Listeria; certain viruses

Identifies possible agents

Routes

Ascending or hematogenous

Identifies access to placenta / fetus

Timing

Ascending route emphasized in trimester two

A gestational association, not proof

An organism, an anatomic route and a gestational interval are different kinds of evidence.

Slide 49 · Pregnancy requires fetal–maternal immune tolerance

The fetal–placental unit is described as a hemi-allograft

Fetal-derived cells are immunologically distinct from the mother.

Successful gestation therefore requires limitation of harmful immune rejection.

The source links tolerance to trophoblast invasion of the maternal uterus.

Immune tolerance is a normal, active requirement—not absence of an immune system.

Slide 50 · Trophoblast invasion requires regulated tolerance

Conceptual pathway (schematic)

Fetal trophoblast

Partially foreign cells at interface

Maternal immunity

Must accommodate and direct invasion

Sustained gestation

Immune rejection must be constrained

The source describes coordinated tolerance of the invasive fetal placental cells.

This is an explanatory schematic of the source narrative.

Slide 51 · Innate and adaptive immunity may be involved

Two components of maternal immune regulation are implicated

Disturbed innate immunity may contribute in some cases.

Adaptive immune abnormalities are also implicated.

The evidence is framed as emerging and mechanistically incomplete.

The excerpt does not supply an immune biomarker panel or validated test cutoff.

Slide 52 · Regulatory T-cell dysfunction is a candidate mechanism

A specific immunologic example in recurrent loss

Regulatory T cells are explicitly identified in the source.

Defective function may participate in recurrent spontaneous abortion in some females.

The textbook does not establish that this accounts for all recurrent losses.

A candidate mechanism is not a universal, clinically proven diagnostic explanation.

Slide 53 · Recurrent miscarriage is etiologically important

The source specifically connects recurrence and immune imbalance

The immunologic paragraph discusses recurrent spontaneous abortion.

Its language is conditional: Such defects “may underlie” some cases.

The same source also acknowledges multiple genetic and maternal contributors.

Avoid assuming an immune cause solely because a loss recurs.

Slide 54 · Immune pathogenesis remains incompletely understood

Do not present a speculative pathway as settled disease biology

The source explicitly characterizes the mechanisms as poorly understood.

Innate/adaptive disturbances and T-cell dysfunction are evidence-based hypotheses.

No immune-based testing or treatment protocol is established in the supplied excerpt.

Scientific uncertainty should appear in teaching, not be suppressed.

Slide 55 · Evidence strength varies across source statements

Source statement

Degree of specification

Appropriate teaching phrasing

Chromosomal anomalies in ~50% early abortuses

Quantified association

Approximately half of early abortuses

Uterine abnormality may disrupt implantation

Qualitative mechanism

Possible structural contributor

T-regulatory dysfunction in some recurrent losses

Conditional, incomplete mechanism

May contribute in a subset

Match the certainty of the lecture claim to the certainty of the text.

Slide 56 · Gestational timing: What can and cannot be inferred

Observation

Supported reading

Not justified

Most losses <12 wk

Early predominance overall

Specific etiology for an individual

Ascending infection in trimester two

Route especially relevant then

All later losses are infectious

Genetic anomalies in early abortuses

Prominent early fetal category

No maternal contribution possible

Timing changes the reasoning context but does not identify the cause.

Slide 57 · Teaching vignette: Early loss and fetal genetics

A pregnancy ends early; Fetal tissue has an abnormal chromosome complement

Which major source category does the tissue finding support?

Answer: Fetal chromosomal abnormality.

Do not infer a specific cause of a parental chromosome abnormality or a recurrence probability from this excerpt.

Interpretive distinction

A tissue result supports a mechanistic category, but does not by itself establish counseling recommendations.

The case is hypothetical; No clinical dataset is presented.

Slide 58 · Teaching vignette: Implantation and uterine anatomy

A uterine cavity has a submucosal mass, followed by an early pregnancy loss

Which category is relevant? Physical anomaly of the uterus.

What mechanism is specifically offered? Prevention or disruption of implantation.

What is not established? That the lesion certainly caused the loss.

An association compatible with the source is not a proven individual causal chain.

Slide 59 · Teaching vignette: Loss in the second trimester

A pregnancy loss follows an ascending cervicovaginal infection

Which route fits the source? Ascending genital-tract spread.

Why is timing relevant? This route in second-trimester losses.

Why is a pathogen still not identified? Route alone is not microbiologic proof.

Route, organism and gestational timing must be distinguished.

Slide 60 · Teaching vignette: Recurrent losses and immunity

Several losses prompt consideration of fetal–maternal tolerance

What immunologic concepts are raised? Innate and adaptive regulation.

Which named cell population? Regulatory T cells.

Does recurrence prove immune rejection? No; The mechanism is incompletely understood.

Recurrent loss cannot be assigned to immunity by default.

Slide 61 · Four clinical clues map to different domains

Clue in vignette

Mechanistic domain

Source limit

Chromosome abnormality

Fetal genomic

Not all losses are genetic

Submucosal mass

Uterine structural

May disrupt implantation

Ascending infection

Infectious route

Agent not proved by route

Recurrent loss

Possible immunologic

Conditional and incompletely understood

Slide 62 · Do not overstate the scope of this excerpt

The topic is etiologic pathology, not a treatment guideline

No ultrasound viability criteria, serial hCG cutoffs or management algorithm are supplied.

No universal pathognomonic miscarriage morphology is documented.

No treatment dose, laboratory diagnostic panel or recurrence probability is provided.

Additional clinical guidelines must be separately sourced before adding those claims.

Slide 63 · Independent mechanisms can converge on pregnancy loss

Conceptual etiologic framework — parallel contributors, not a causal sequence

Fetal factors

Chromosomal or subtler genetic defects

Maternal factors

Endocrine • structural • vascular

Interface factors

Infection • altered immune tolerance

Potential shared endpoint: Spontaneous abortion (<20 weeks)

These are alternative domains; The textbook does not establish a unique cause for most individual early losses.

Slide 64 · Core synthesis: Five exam-relevant distinctions

Translate the pathology excerpt into defensible statements

Recognized versus assay-detected early loss: Detection changes observed frequency.

Aneuploidy versus polyploidy versus translocation: Different genetic abnormalities.

Structural versus vascular maternal factors: Distinct etiologic domains.

Ascending versus hematogenous infection: Distinct placental access routes.

Tolerance biology versus established immune causation: Avoid overstatement.

Slide 65 · Assessment: Match source statement to mechanism

Clinical or textual finding

Most appropriate domain

Abnormal fetal chromosome count

Fetal chromosomal abnormality

Submucosal leiomyoma affecting implantation

Uterine structural

Antiphospholipid antibody syndrome

Maternal vascular

Cervicovaginal ascending infection

Infectious

T-regulatory-cell defect proposed in recurrent loss

Possible maternal–fetal immune imbalance

The table tests recognition, not case-specific causation.

Slide 66 · Core source and scope

Primary reading

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).

Chapter 22, The Female Genital Tract; 'Spontaneous Abortion,' printed pp. 934–935.

Anatomical context: 'Gestational and Placental Disorders,' printed pp. 933–934; Fig. 22.44 descriptive caption.

No copyrighted textbook photographs are reproduced. All teaching graphics are editable native schematics.